相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Neoadjuvant pembrolizumab improves eventfree survival in melanoma
T. Schwarz
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2023)
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
Sapna P. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2023)
Surgeon Assessment of the Technical Impact of Neoadjuvant Systemic Therapy on Operable Stage III Melanoma
Tina J. Hieken et al.
ANNALS OF SURGICAL ONCOLOGY (2022)
Time interval between diagnostic excision-biopsy of a primary melanoma and sentinel node biopsy: effects on the sentinel node positivity rate and survival outcomes
Mary -Ann El Sharouni et al.
EUROPEAN JOURNAL OF CANCER (2022)
Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma
Oliver J. Kennedy et al.
EUROPEAN JOURNAL OF CANCER (2022)
The NADINA trial: A multicenter, randomised, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma.
Minke W. Lucas et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Primary ipilimumab/nivolumab followed by adjuvant nivolumab in patients with locally advanced or oligometastatic melanoma: Update on outcome.
Emilia Cocorocchio et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Delays in the surgical treatment of melanoma are associated with worsened overall and melanoma-specific mortality: A population-based analysis
David D. Xiong et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)
Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial
Irene L. M. Reijers et al.
NATURE MEDICINE (2022)
Neoadjuvant relatlimab and nivolumab in resectable melanoma
Rodabe N. Amaria et al.
NATURE (2022)
Trends in Melanoma Phase 3 Clinical Trials since 2010: Is there Hope for Advanced Melanoma Therapies beyond Approved Treatment Mechanisms?
Hanna H. Kakish et al.
CANCERS (2022)
Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma
Jeffrey S. Weber et al.
EUROPEAN JOURNAL OF CANCER (2021)
Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial
R. Dummer et al.
NATURE MEDICINE (2021)
Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma
E. A. Rozeman et al.
NATURE MEDICINE (2021)
Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)
Alexander M. Menzies et al.
NATURE MEDICINE (2021)
Neoadjuvant Cytoreductive Treatment With BRAF/MEK Inhibition of Prior Unresectable Regionally Advanced Melanoma to Allow Complete Surgical Resection, REDUCTOR A Prospective, Single-arm, Open-label Phase II Trial
Stephanie A. Blankenstein et al.
ANNALS OF SURGERY (2021)
Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG3 antibody relatlimab (rela) for patients (pts) with resectable clinical stage III melanoma.
Rodabe Navroze Amaria et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Efficacy of imiquimod in the management of lentigo maligna.
Brigitte Dréno et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
Ralf Gutzmer et al.
LANCET (2020)
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
Reinhard Dummer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial
Elisa A. Rozeman et al.
LANCET ONCOLOGY (2019)
Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial
Georgina V. Long et al.
LANCET ONCOLOGY (2019)
Current Immunotherapy Practices in Melanoma
Luke D. Rothermel et al.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA (2019)
Neo-DREAM study investigating Daromun for the treatment of clinical stage IIIB/C melanoma
John T. Miura et al.
FUTURE ONCOLOGY (2019)
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
Georgina Long et al.
LANCET ONCOLOGY (2019)
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial
Rodabe N. Amaria et al.
LANCET ONCOLOGY (2018)
LBA42OpACIN-neo: A multicenter phase II study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO)
C U Blank et al.
ANNALS OF ONCOLOGY (2018)
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Rodabe N. Amaria et al.
NATURE MEDICINE (2018)
Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma
Christian U. Blank et al.
NATURE MEDICINE (2018)
Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma
Tuba N. Gide et al.
CLINICAL CANCER RESEARCH (2018)
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Cancer acidity: An ultimate frontier of tumor immune escape and a novel target of immunomodulation
Veronica Huber et al.
SEMINARS IN CANCER BIOLOGY (2017)
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
A. M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
Jing Liu et al.
CANCER DISCOVERY (2016)
Extracellular acidity strengthens mesenchymal stem cells to promote melanoma progression
Silvia Peppicelli et al.
CELL CYCLE (2015)
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H. I. Andtbacka et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Preliminary Results from a Prospective Trial of Preoperative Combined BRAF and MEK-Targeted Therapy in Advanced BRAF Mutation-Positive Melanoma
Adam S. Johnson et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2015)
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
Alexander M. M. Eggermont et al.
LANCET ONCOLOGY (2015)
Neoadjuvant Therapy in the Treatment of Breast Cancer
Mediget Teshome et al.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA (2014)
A Phase 2 Trial of Complete Resection for Stage IV Melanoma Results of Southwest Oncology Group Clinical Trial S9430
Jeffrey A. Sosman et al.
CANCER (2011)
Phase II trial of neoadjuvant temozolomide in resectable melanoma patients
G. D. Shah et al.
ANNALS OF ONCOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Proton pump inhibition induces autophagy as a survival mechanism following oxidative stress in human melanoma cells
M. L. Marino et al.
CELL DEATH & DISEASE (2010)
Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma
Karl D. Lewis et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
分享论文
